Pharmacovigilance in Canada: What Drug Sponsors Must Report After Market Authorization

Most drug sponsors I work with spend years building toward their Notice of Compliance — and then treat approval as a finish line. It isn’t. In Canada, market authorization triggers a new set of obligations under the Food and Drug Regulations that are just as consequential as anything required during the submission process, and the consequences of getting them wrong have sharpened considerably since Vanessa’s Law came into force.

Pharmacovigilance — the systematic collection, assessment, and reporting of adverse drug reactions after a product reaches patients — is regulated under Section C.01.016 of the Food and Drug Regulations, alongside guidance documents that Health Canada has harmonized with ICH E2A, E2C(R2), and E2D. What surprises many sponsors is how much operational infrastructure these obligations actually require, and how frequently Health Canada finds deficiencies when it looks.

What Section C.01.016 Actually Requires

The core obligation is straightforward on paper: market authorization holders (MAHs) must report adverse reactions to Health Canada via the Canada Vigilance Program. But the timelines, scope, and formatting requirements are where most programs run into trouble.

Expedited reporting — 15 calendar days — applies to serious unexpected adverse drug reactions that occur in Canada. “Unexpected” means the reaction isn’t described in the current Canadian Product Monograph, regardless of whether it’s documented in foreign labelling or the published scientific literature. These go to Health Canada’s Marketed Health Products Directorate using a CIOMS I form or equivalent, submitted through the MedEffect Canada portal.

Serious unexpected foreign reactions — those occurring outside Canada — also trigger the 15-day clock in most circumstances, provided there’s a reasonable possibility the drug caused the reaction. This catches sponsors off guard more often than you’d expect. A labelling update in the U.S. doesn’t automatically satisfy the Canadian reporting obligation; you may still need a separate expedited submission.

Serious expected reactions (those already listed in the Product Monograph) generally don’t require expedited reporting in the post-market setting, unless they arise from an ongoing Canadian clinical trial, where Part C, Division 5 of the Food and Drug Regulations applies a 30-day reporting window.

Non-serious reactions — domestic or foreign — feed into annual summary reports rather than individual case submissions.

Canada Vigilance receives approximately 65,000 to 70,000 individual case safety reports annually across all health product categories. A meaningful share are manufacturer-reported, and Health Canada tracks whether MAHs are submitting cases within scope and on time.

How Vanessa’s Law Changed What Non-Compliance Costs

Before 2019, the maximum fine for a violation of the Food and Drugs Act was $5,000. That figure became historically irrelevant when Bill C-17 — formally the Protecting Canadians from Unsafe Drugs Act, known as Vanessa’s Law — received Royal Assent and its key provisions took effect.

The law was named after Vanessa Young, a 15-year-old from Ontario who died in 2000 after taking cisapride (Prepulsid). The drug remained on the Canadian market for years after serious cardiac arrhythmia risks had been identified internationally. Vanessa’s Law was designed to close the regulatory gaps that allowed that to happen.

Today, a serious violation of the Food and Drugs Act can attract fines of up to $5 million per day for corporations. Health Canada also gained explicit authority to:

• Order mandatory product recalls (previously only voluntary compliance was enforceable through the Food and Drug Regulations)
• Require MAHs to conduct post-market studies as a condition of continued authorization
• Compel label changes, including Product Monograph updates, without waiting for sponsor agreement
• Access clinical information held by authorization holders without a court order in certain circumstances

The shift from a voluntary to a compulsory enforcement framework matters in practice. Health Canada used its new recall authority multiple times within the first three years of Vanessa’s Law being fully operational, and it has exercised its label change powers in cases where MAHs disputed the strength of an emerging safety signal. The era of negotiating indefinitely while a potential risk sits unaddressed is largely over.

What “Serious” and “Unexpected” Mean Under Health Canada’s Definitions

Health Canada has adopted the ICH E2A definition for serious adverse drug reactions. A reaction qualifies as serious if it results in any of the following:

1. Death
2. A life-threatening condition
3. Inpatient hospitalization or prolongation of existing hospitalization
4. A persistent or significant disability or incapacity
5. A congenital anomaly or birth defect
6. A medically important condition — one that may jeopardize the patient or require intervention to prevent one of the outcomes above

The sixth category generates the most interpretation questions. Drug-induced liver injury that resolves without hospitalization may still qualify. So might a hypersensitivity reaction that required epinephrine but didn’t result in admission. The answer depends on whether intervention prevented a serious outcome, which requires medical judgment at the case level. Most robust pharmacovigilance programs designate a medically qualified assessor — typically a physician or PharmD — for case-level seriousness determinations.

“Unexpected” is equally important — and equally nuanced. If your Canadian Product Monograph lists a reaction in an adverse events table but doesn’t describe the frequency, severity, or clinical specificity of what’s being reported in the incoming case, that case may still qualify as unexpected. These are judgment calls. Documenting the rationale is as important as making the right call; a Health Canada inspector reviewing your case files will look for both.

Periodic Benefit-Risk Evaluation Reports: Canada’s PBRER Obligations

For MAHs with products on the Canadian market, Health Canada expects Periodic Benefit-Risk Evaluation Reports (PBRERs) in alignment with ICH E2C(R2). PBRERs replaced Periodic Safety Update Reports (PSURs) as the required aggregate safety submission format, and the transition brought both structural and content changes that some sponsors still haven’t fully implemented.

The PBRER is anchored to an International Birth Date (IBD) — the date of first market authorization anywhere in the world — with data lock points at 6 months, 1 year, and 2 years after the IBD, then every 3 years once the product is considered well-established. Health Canada generally accepts a global IBD and allows sponsors with EU or U.S. products to submit the same core PBRER to multiple regulators. But it expects a Canada-specific appendix covering Canadian sales volumes, Canadian case counts by seriousness and expectedness, and any Canadian labelling differences from the global Product Monograph.

Waiver provisions exist. Products with very low Canadian uptake — those marketed in negligible volumes or used only within clinical trial programs — can request a PBRER waiver through the Marketed Health Products Directorate. Health Canada reviews these case by case, and approval isn’t automatic.

One thing Health Canada doesn’t require, and that sometimes confuses sponsors accustomed to EMA submissions, is a standalone Risk Management Plan (RMP). If your product has an EU RMP, Health Canada expects awareness of it and alignment where relevant — but a separate Canadian RMP isn’t a routine post-market requirement, though it can be requested as a condition of authorization.

Five Pharmacovigilance Gaps We See Repeatedly

In our work supporting pharmaceutical sponsors across Canada, the weakest points in pharmacovigilance programs cluster around the same five deficiencies:

1. No systematic literature monitoring. Health Canada expects MAHs to conduct structured searches of the published scientific literature for adverse reaction reports referencing their products. Weekly searches of MEDLINE and Embase, indexed against relevant MedDRA preferred terms and the current Canadian Product Monograph, should be documented and reviewed by a medical assessor. Many smaller sponsors are simply not doing this — or doing it inconsistently without records.

2. Signal detection is reactive, not proactive. Reviewing your adverse event database through a disproportionality analysis — calculating Information Component (IC) scores or Proportional Reporting Ratios (PRRs) on a periodic basis — isn’t just good practice; it’s increasingly expected as evidence of a functioning signal management process. Health Canada inspectors reviewing pharmacovigilance system documentation will look for it, and finding no formal signal detection methodology is a documented inspection gap.

3. Foreign serious unexpected reactions are under-reported. If your parent organization in the United States or Europe receives a serious unexpected ADR for a product also marketed in Canada, that case generally needs to be forwarded to your Canadian pharmacovigilance system and assessed for reporting to Health Canada. The process for ensuring global case forwarding is functional, documented, and routinely verified is often informal or missing at smaller Canadian affiliates.

4. SOPs aren’t version-controlled or followed. Written procedures for adverse reaction intake, triage, medical review, database entry, and regulatory submission exist at most organizations. Whether staff consistently follow them — and whether the documents reflect actual current practice — is another matter. Health Canada GMP documentation standards apply to pharmacovigilance SOPs the same way they apply to manufacturing records: documents should reflect reality, and reality should reflect documents.

5. The responsible person is under-resourced. Canada doesn’t legislate a “Qualified Person for Pharmacovigilance” the way the EU does under Directive 2001/83/EC — but Health Canada expects a named individual to be responsible for the pharmacovigilance system, with documented authority and sufficient dedicated time. A regulatory affairs manager covering pharmacovigilance alongside twelve other portfolios is a recurring inspection finding.

Where to Start if Your Program Needs a Review

If it’s been more than two years since your last pharmacovigilance system audit, start with a case completeness check. Pull every domestic serious case from the past 12 months and verify the submission date against the receipt date. Fifteen calendar days is tighter than it sounds, and the clock starts earlier than many sponsors realize — not from when you received a formal written report, but from the moment anyone at your organization first became aware of the case, including through a customer service call, a sales rep conversation, or a social media post.

Then check your Product Monograph against your global labelling. If your U.S. prescribing information or EU Summary of Product Characteristics includes adverse reaction terms, frequencies, or warnings that your Canadian PM doesn’t, you may have expectedness reclassifications that affect your reporting obligations retroactively — and that affect how your incoming cases should be triaged going forward.

And document your decisions. Health Canada doesn’t just want a compliant pharmacovigilance system — it wants evidence that you have one.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• API and Raw Material Testing for Canadian Drug Sponsors — Qalitex Laboratories provides ISO 17025-accredited testing for APIs, excipients, and finished products supporting Canadian MAH supplier qualification programs.
• EU Post-Market Safety Reporting and RMP Compliance — Care Europe helps manufacturers align EU pharmacovigilance obligations — including EMA RMPs and PBRER submissions — with parallel Canadian regulatory requirements.